CERS Earnings Prediction
The chart below shows how CERS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CERS sees a +0.34% change in stock price 10 days leading up to the earnings, and a -3.57% change 10 days following the report. On the earnings day itself, the stock moves by -0.26%. This data can give you a slight idea of what to expect for the next quarter's release.
CERS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
50.66M
7.21%
0.27%
Gross Margin
60.88%
-1.81%
2.16%
Operating Margin
-1.90%
-75.36%
-74.97%
Net Margin
-5.79%
-62.45%
-49.34%
EPS
-0.02
-50.00%
-33.33%
No Data Available
CERS Earnings Analysis
Cerus Corp Corporation (CERS.O) Earnings Conference Call
Positive
Q3 Product Revenue Growth: Product revenue for the third quarter of 2024 was $46 million, representing year-over-year growth of 16%.
Product Revenue Increase: Product revenue for the first nine months of the year reached $129.5 million, up 18% from the prior year period.
Platelet Sales Contribution: North American platelet sales continued to be the major contributor to our product revenue growth during the quarter.
Product Revenue Increase: In the U.S., product revenues exceeded prior year levels by 17%, with Canadian Blood Services now at 100% entering the third quarter.
Product Gross Profit Increase: For the third quarter, we posted product gross profit of $26.2 million compared to $21.8 million during the prior year period, an increase of 20% year-over-year.
Negative
Product Revenue Growth: Product revenue for the third quarter of 2024 was $46 million, which is a year-over-year growth of only 16%.
Operating Expenses Reduction: Operating expenses totaled $31.8 million, down 8% from $34.5 million in Q3 of 2023, indicating a reduction in operational spending.
R&D Expense Decline: R&D expenses totaled $14 million compared to $16.8 million during the prior year period, reflecting a 17% decline.
Net Loss Reduction: Net loss attributable to Cerus for Q3 narrowed by 60% to $2.9 million compared to $7.3 million for the prior year period, but still indicates ongoing financial challenges.
Government Contract Revenue Decline: Government contract revenue totaled $4.6 million in Q3 compared to $7.5 million for the prior year period, showing a significant drop in government-related income.
CERS FAQs
How does CERS typically perform around its earnings report dates?
Is Cerus Corporation (CERS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CERS Earning Call Sentiment
Cerus Corporation (CERS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CERS.O
-1.89%Positive
Cerus showed strong financial performance with 16% YoY revenue growth, improved EBITDA, and positive cash flow. The raised revenue guidance and expansion plans, particularly for the INTERCEPT Blood System, indicate growth potential. However, the lack of shareholder return plans and vague guidance on IFC revenue are slight negatives. Overall, the positive financial metrics and strategic advancements outweigh these concerns, suggesting a positive stock price reaction.